<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04199910</url>
  </required_header>
  <id_info>
    <org_study_id>4bHC kirroosissa</org_study_id>
    <nct_id>NCT04199910</nct_id>
  </id_info>
  <brief_title>4beta-hydroxycholesterol in Cirrhosis</brief_title>
  <official_title>4beta-hydroksikolesteroli Maksakirroosissa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oulu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oulu</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to evaluate the levels of oxysterols and especially 4beta-hydroxycholesterol in
      patients with liver cirrhosis. Three cirrhosis cohorts are recruited: patients treated with
      spironolactone, patients treated with rifaximin, patients without spironolactone or
      rifaximin. Also three other control cohorts are recruited: patients with pneumonia, patients
      with Crohn's disease, patients with ulcerative colitis. The effect of the cirrhosis and its
      medications spironolactone and rifaximin are compared to control groups.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Blood 4beta-hydroxycholesterol concentration</measure>
    <time_frame>At the time point of the blood collection - cross-sectional. One day.</time_frame>
    <description>Blood 4beta-hydroxycholesterol concentration</description>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Cirrhosis, Liver</condition>
  <arm_group>
    <arm_group_label>Liver cirrhosis with spironolactone</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Liver cirrhosis with rifaximin</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Liver cirrhosis without spironolactone or rifaximin</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Pneumonia</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Crohn's disease</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Ulcerative colitis</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>There is no intervention, only research blood samples are collected</intervention_name>
    <description>Research blood samples collected</description>
    <arm_group_label>Crohn's disease</arm_group_label>
    <arm_group_label>Liver cirrhosis with rifaximin</arm_group_label>
    <arm_group_label>Liver cirrhosis with spironolactone</arm_group_label>
    <arm_group_label>Liver cirrhosis without spironolactone or rifaximin</arm_group_label>
    <arm_group_label>Pneumonia</arm_group_label>
    <arm_group_label>Ulcerative colitis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with cirrhosis, pneumonia, Crohn's disease or colitis ulcerosa treated in the ward
        42 of the Oulu University Hospital
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with cirrhosis, pneumonia, Crohn's disease or colitis ulcerosa

          -  Treated in the ward 42 of the Oulu University Hospital

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janne Hukkanen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oulu University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Janne Hukkanen, MD</last_name>
    <phone>+35883156212</phone>
    <email>janne.hukkanen@oulu.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <zip>90029 OYS</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janne Hukkanen, MD, PhD</last_name>
      <phone>+358-8-3156212</phone>
      <email>janne.hukkanen@oulu.fi</email>
    </contact>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 11, 2019</study_first_submitted>
  <study_first_submitted_qc>December 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2019</study_first_posted>
  <last_update_submitted>December 13, 2019</last_update_submitted>
  <last_update_submitted_qc>December 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Oulu</investigator_affiliation>
    <investigator_full_name>Janne Hukkanen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

